Spotlighting Clinical Trials of TREM2 Agonists Against Alzheimer’s Disease
Time: 8:30 am
day: Day One
Details:
• Overviewing the on-going clinical landscape of TREM2 therapeutics
• Detailing currently employed biomarkers – what they are and what reveal
• Outlining high-level modality considerations for rare vs common neurodegenerative diseases
• Making the case for precision-based clinical development
